CDK6 Degradation Is Counteracted by p16INK4A and p18INK4C in AML

Medientyp: E-Artikel

Titel: CDK6 Degradation Is Counteracted by p16INK4A and p18INK4C in AML

Beteiligte: Schmalzbauer, Belinda S.; Thondanpallil, Teresemary; Heller, Gerwin; Schirripa, Alessia; Sperl, Clio-Melina; Mayer, Isabella M.; Knab, Vanessa M.; Nebenfuehr, Sofie; Zojer, Markus; Mueller, André C.; Fontaine, Frédéric; Klampfl, Thorsten; Sexl, Veronika; Kollmann, Karoline

Erschienen: MDPI AG, 2022

Sprache: Englisch

DOI: 10.3390/cancers14061554

ISSN: 2072-6694

Entstehung:

Anmerkungen:

Beschreibung: Cyclin-dependent kinase 6 (CDK6) represents a novel therapeutic target for the treatment of certain subtypes of acute myeloid leukaemia (AML). CDK4/6 kinase inhibitors have been widely studied in many cancer types and their effects may be limited by primary and secondary resistance mechanisms. CDK4/6 degraders, which eliminate kinase-dependent and kinase-independent effects, have been suggested as an alternative therapeutic option. We show that the efficacy of the CDK6-specific protein degrader BSJ-03-123 varies among AML subtypes and depends on the low expression of the INK4 proteins p16INK4A and p18INK4C. INK4 protein levels are significantly elevated in KMT2A-MLLT3+ cells compared to RUNX1-RUNX1T1+ cells, contributing to the different CDK6 degradation efficacy. We demonstrate that CDK6 complexes containing p16INK4A or p18INK4C are protected from BSJ-mediated degradation and that INK4 levels define the proliferative response to CDK6 degradation. These findings define INK4 proteins as predictive markers for CDK6 degradation-targeted therapies in AML.

Zugangsstatus: Freier Zugang

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: